Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. ABL Diagnostics's shares outstanding for the quarter that ended in Dec. 2025 was 16.07 Mil.
ABL Diagnostics's quarterly shares outstanding
declined
from Jun. 2025 (16.08 Mil) to Dec. 2025 (16.07 Mil).
It means ABL Diagnosticsbought back shares from Jun. 2025 to Dec. 2025 .
ABL Diagnostics's annual shares outstanding
declined
from Dec. 2024 (16.09 Mil) to Dec. 2025 (16.07 Mil).
It means ABL Diagnosticsbought back shares from Dec. 2024 to Dec. 2025 .
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
ABL Diagnostics Shares Outstanding (EOP) Related Terms
ABL Diagnostics Shares Outstanding (EOP) Historical Data
* Premium members only.
The historical data trend for ABL Diagnostics's Shares Outstanding (EOP) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:ABLD vs VEEV, BTSG, TEM: Shares Outstanding (EOP) Comparison
For the Health Information Services subindustry, ABL Diagnostics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ABL Diagnostics Shares Outstanding (EOP) vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, ABL Diagnostics's Shares Outstanding (EOP) distribution charts can be found below:
* The bar in red indicates where ABL Diagnostics's Shares Outstanding (EOP) falls into.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
What does a Shares Outstanding (EOP) of 16.07 Mil mean?
ABL Diagnostics (XPAR:ABLD) has a Shares Outstanding (EOP) of 16.07 Mil as of Dec. 2025. The total shares a company has outstanding, at period-end. View historical data on ABL Diagnostics and its competitors.
Is ABL Diagnostics' Shares Outstanding (EOP) too high?
ABL Diagnostics' current Shares Outstanding (EOP) is 16.07 Mil. Overall, ABL Diagnostics has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ABL Diagnostics' Shares Outstanding (EOP) compare to VEEV and BTSG?
ABL Diagnostics' Shares Outstanding (EOP) of 16.07 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Healthcare Providers & Services company?
A good Shares Outstanding (EOP) depends on the Healthcare Providers & Services industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on ABL Diagnostics and its competitors. ABL Diagnostics's current Shares Outstanding (EOP) is 16.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABL Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, ABL Diagnostics (XPAR:ABLD) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.71, compared to a current price of €2.66 — trading 65.5% below its estimated fair value. The current Shares Outstanding (EOP) is 16.07 Mil. ABL Diagnostics' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For ABL Diagnostics (XPAR:ABLD), the current Shares Outstanding (EOP) is 16.07 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ABL Diagnostics (XPAR:ABLD) Overvalued in 2026?
Based on GuruFocus' analysis, ABL Diagnostics stock appears to be undervalued.
The current stock price of €2.66 is trading 65.5% below its estimated GF Value™ of €7.71.
GuruFocus considers ABL Diagnostics to be Significantly Undervalued.
Key valuation signals for XPAR:ABLD:
Shares Outstanding (EOP): 16.07 Mil
GF Value™: €7.71 vs. price of €2.66 (65.5% below fair value)
No single metric tells the full story. See the XPAR:ABLD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
51GF Score
Get the complete analysis for XPAR:ABLD
Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ABLD has been successfully added to your 
